Influence of an inducible nitric oxide synthase promoter variant on clinical variables in patients with coronary artery disease

被引:28
作者
Morris, BJ [1 ]
Glenn, CL
Wilcken, DEL
Wang, XL
机构
[1] Univ Sydney, Basic & Clin Genom Lab, Dept Physiol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia
[3] Prince Wales Hosp, Cardiovasc Genet Lab, Sydney, NSW 2031, Australia
[4] Univ New S Wales, Ctr Thrombosis & Vasc Res, Sydney, NSW 2031, Australia
关键词
angina; coronary artery disease; nitric oxide synthase; plasma glucose;
D O I
10.1042/CS20000223
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pathophysiological processes in coronary artery disease (CAD) are influenced by genetic factors. Since (i) inducible nitric oxide synthase (iNOS) has important cardiovascular effects, and (ii) the promoter of the iNOS gene (NOS2A) is genetically modulated by a 4 bp insertion/deletion (+ / -) polymorphism located 0.7 kb upstream, we decided to examine the influence of this variant on clinical variables in 856 CAD patients of Anglo-Celtic/Northern European extraction. We found that 2% of CAD patients were homozygous for the + allele, and 19% were heterozygous. Males made up 74% of the patient group, and in these the + allele was associated with 38% higher plasma glucose levels (P = 0.005), a 4.8% elevation in the waist/hip ratio (P = 0.009) and a 48% greater frequency of unstable angina (P = 0.014). The + allele, by influencing iNOS expression, could thus contribute to indices of insulin resistance and angina severity in male CAD patients.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 29 条
[1]   Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors [J].
Alfon, J ;
Guasch, JF ;
Berrozpe, M ;
Badimon, L .
ATHEROSCLEROSIS, 1999, 145 (02) :325-331
[2]   Histochemical evidence for inducible nitric oxide synthase in advanced but non-ruptured human atherosclerotic carotid arteries [J].
Behr-Roussel, D ;
Rupin, A ;
Sansilvestri-Morel, P ;
Fabiani, JN ;
Verbeuren, TJ .
HISTOCHEMICAL JOURNAL, 2000, 32 (01) :41-51
[3]  
Bellamy R, 1997, CLIN GENET, V52, P192
[4]  
Buttery LDK, 1996, LAB INVEST, V75, P77
[5]   Sequence diversity in 36 candidate genes for cardiovascular disorders [J].
Cambien, F ;
Poirier, O ;
Nicaud, V ;
Herrmann, SM ;
Mallet, C ;
Ricard, S ;
Behague, I ;
Hallet, V ;
Blanc, H ;
Loukaci, V ;
Thillet, J ;
Evans, A ;
Ruidavets, JB ;
Arveiler, D ;
Luc, G ;
Tiret, L .
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (01) :183-191
[6]  
Engeli S., 2000, International Journal of Obesity, V24, pS28
[7]   Different frequencies of inducible nitric oxide synthase genotypes in older hypertensives [J].
Glenn, CL ;
Wang, WYS ;
Morris, BJ .
HYPERTENSION, 1999, 33 (04) :927-932
[8]   CCTTT-repeat polymorphism in the human NOS2-promoter confers low risk of diabetic nephropathy in type 1 diabetic patients [J].
Johannesen, J ;
Tarnow, L ;
Parving, HH ;
Nerup, J ;
Pociot, F .
DIABETES CARE, 2000, 23 (04) :560-562
[9]   Roles of PPARs in health and disease [J].
Kersten, S ;
Desvergne, B ;
Wahli, W .
NATURE, 2000, 405 (6785) :421-424
[10]  
KHOURY MJ, 1993, MONOGRAPHS EPIDEMIOL, V19